
Eli Lilly and its partner Boehringer Ingelheim have been granted special status at the FDA for their drug Jardiance, to speed up its journey to market as a preventive therapy for heart failure in patients who are not suffering from reduced ventricle functioning.
In a press release on Thursday, the companies reported that Jardiance has been given a "priority review" label, which cuts down processing time at the agency from ten to six months.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app